Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Why We Need Fast-Acting Anxiety Relief Now More Than Ever Anxiety isn’t just feeling nervous before a big event—it can be relentless, overwhelming, and even debilitating. Traditional treatments like ...

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

Detailed price information for Awakn Life Sciences Corp (AWKNF) from The Globe and Mail including charting and trades.

Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in the US alone.